Resverlogix completes patient recruitment in Phase 2 ASSERT clinical study
February 8, 2010 by leonardzehr · Leave a Comment
Resverlogix (TSX:RVX) has completed patient enrolment in the Phase 2 ASSERT clinical study of its lead cholesterol drug RVX-208, five months ahead of schedule. “At this rate we could be seeing the final dosed patient in May, 2010,” CEO Donald McCaffrey said in a statement. “In the second half of 2010, we look forward to [...]
Listen to BioTuesdays 
